Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Dermira Inc
DERM | US
6.83
USD-0.08
-1.16%
DERM | US
Loading StockChartView...
About Dermira Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
25/03/2026
Close
6.83
Open
7.05
High
7.21
Low
6.65
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane an oral isotretinoin drug to treat severe recalcitrant acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi a topical minocycline treatment for inflammatory lesions; Ximino an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets minocycline hydrocholoride capsules and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech Inc.
View LessDERM | US
Risk
50.3
Sharpe
-0.01
Luna's Score
24/100
Recommendation
Sell
Luna says (DERM | US)
What's Working
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
57.3%1 month
50.3%3 months
53.0%6 months
53.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
47.08
Fwd. PE
17.21
Price to book
11.52
Debt to equity
2.02
Debt to assets
0.35
Ent. to EBITDA
21.68
Ent. to rev.
1.62
PEG
-
Other Fundamentals
EBITDA
5.38M
MarketCap
141.57M
MarketCap(USD)
141.57M
Div. yield
-
Op. margin
-19.70
Erngs. growth
-
Rev. growth
-13.50
Ret. on equity
14.92
Short ratio
2.10
Short perc.
2.03
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.75
Range1M
2.50
Range3M
3.00
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.24
Price X volume
1.58M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 21.68 | 0.53 | Expensive |
| Ent. to Revenue | 1.62 | 3,967.00 | Cheaper |
| PE Ratio | 47.08 | 41.03 | Par |
| Price to Book | 11.52 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 53.04 | 72.80 | Lower Risk |
| Debt to Equity | 2.02 | -1.23 | Expensive |
| Debt to Assets | 0.35 | 0.25 | Expensive |
| Market Cap | 141.57M | 3.66B | Emerging |
